British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008

8.2.4 Recommendations 9.0 Guidelines for the management of metabolic complications in HIV infection 9.1 Lipid abnormalities 9.1.1Evaluation of risk 9.1.2Which calculator to use 9.1.3Treatment of lipid disorders 9.1.4Switching ART 9.1.5Lipid-lowering treatments 9.1.6Which agents to use 9.2 Insulin resistance and diabetes 9.2.1 Recommendations for assessment and monitoring of insulin resistance 9.2.2 Treatment 9.3 Prevention and management of lipodystrophy 9.3.1 Assessment of lipodystrophy 9.4 Management of lipoatrophy 9.4.1 Surgical intervention 9.5 Lipohypertrophy 9.5.1 Prevention 9.5.2Pharmacological intervention 9.5.3Surgical therapy 9.6 Lactic acidosis and hyperlactataemia 10.0 Recommendations for resistance testing 10.1 Treatment-naı ¨ve patients 10.2 Treatment-experienced patients 10.3 Key principles in the interpretation of antiretroviral resistance in treatment-experienced patients 10.3.1 General recommendations 11.0 Adherence 11.1 Assessing adherence 11.2 Interventions to support adherence 11.3 Costs 12.0 Pharmacology 12.1 Drug interactions 12.2 Therapeutic drug monitoring (TDM) 12.3 Stopping therapy 12.4 Pharmacogenetics 13.0 HIV testing 14.0 Cost-effectiveness 15.0 Conflict of interest 16.0 References 17.0 Appendix